JP2014517001A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014517001A5 JP2014517001A5 JP2014514097A JP2014514097A JP2014517001A5 JP 2014517001 A5 JP2014517001 A5 JP 2014517001A5 JP 2014514097 A JP2014514097 A JP 2014514097A JP 2014514097 A JP2014514097 A JP 2014514097A JP 2014517001 A5 JP2014517001 A5 JP 2014517001A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- ester
- induced
- traumatic
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010053476 Traumatic haemorrhage Diseases 0.000 claims 16
- 150000001875 compounds Chemical class 0.000 claims 12
- 150000002148 esters Chemical class 0.000 claims 11
- 150000003839 salts Chemical class 0.000 claims 11
- 229960000981 artemether Drugs 0.000 claims 6
- 229960004191 artemisinin Drugs 0.000 claims 6
- BLUAFEHZUWYNDE-NNWCWBAJSA-N artemisinin Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2OC(=O)[C@@H]4C BLUAFEHZUWYNDE-NNWCWBAJSA-N 0.000 claims 6
- 229930101531 artemisinin Natural products 0.000 claims 6
- 229960002521 artenimol Drugs 0.000 claims 6
- BJDCWCLMFKKGEE-ISOSDAIHSA-N artenimol Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2O[C@H](O)[C@@H]4C BJDCWCLMFKKGEE-ISOSDAIHSA-N 0.000 claims 6
- 229960004991 artesunate Drugs 0.000 claims 6
- FIHJKUPKCHIPAT-AHIGJZGOSA-N artesunate Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2O[C@@H](OC(=O)CCC(O)=O)[C@@H]4C FIHJKUPKCHIPAT-AHIGJZGOSA-N 0.000 claims 6
- 229930016266 dihydroartemisinin Natural products 0.000 claims 6
- SXYIRMFQILZOAM-HVNFFKDJSA-N dihydroartemisinin methyl ether Chemical compound C1C[C@H]2[C@H](C)CC[C@H]3[C@@H](C)[C@@H](OC)O[C@H]4[C@]32OO[C@@]1(C)O4 SXYIRMFQILZOAM-HVNFFKDJSA-N 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 5
- 208000010125 myocardial infarction Diseases 0.000 claims 5
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims 4
- 239000013543 active substance Substances 0.000 claims 4
- 230000008816 organ damage Effects 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 208000010496 Heart Arrest Diseases 0.000 claims 3
- 102100037907 High mobility group protein B1 Human genes 0.000 claims 3
- 101710168537 High mobility group protein B1 Proteins 0.000 claims 3
- 239000008280 blood Substances 0.000 claims 3
- 210000004369 blood Anatomy 0.000 claims 3
- 239000003446 ligand Substances 0.000 claims 3
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 2
- 102000004145 Annexin A1 Human genes 0.000 claims 2
- 108090000663 Annexin A1 Proteins 0.000 claims 2
- 102000003964 Histone deacetylase Human genes 0.000 claims 2
- 108090000353 Histone deacetylase Proteins 0.000 claims 2
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 claims 2
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 claims 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- 208000027418 Wounds and injury Diseases 0.000 claims 2
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 2
- 239000004067 bulking agent Substances 0.000 claims 2
- 230000006378 damage Effects 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 208000014674 injury Diseases 0.000 claims 2
- 230000010410 reperfusion Effects 0.000 claims 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims 2
- 235000017557 sodium bicarbonate Nutrition 0.000 claims 2
- 102000009310 vitamin D receptors Human genes 0.000 claims 2
- 108050000156 vitamin D receptors Proteins 0.000 claims 2
- 208000010444 Acidosis Diseases 0.000 claims 1
- BOJKULTULYSRAS-OTESTREVSA-N Andrographolide Chemical compound C([C@H]1[C@]2(C)CC[C@@H](O)[C@]([C@H]2CCC1=C)(CO)C)\C=C1/[C@H](O)COC1=O BOJKULTULYSRAS-OTESTREVSA-N 0.000 claims 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims 1
- BQENDLAVTKRQMS-SBBGFIFASA-L Carbenoxolone sodium Chemical compound [Na+].[Na+].C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C([O-])=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](OC(=O)CCC([O-])=O)C1(C)C BQENDLAVTKRQMS-SBBGFIFASA-L 0.000 claims 1
- 102000003951 Erythropoietin Human genes 0.000 claims 1
- 108090000394 Erythropoietin Proteins 0.000 claims 1
- 239000004378 Glycyrrhizin Substances 0.000 claims 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 1
- 206010019196 Head injury Diseases 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 102000002791 Interleukin-8B Receptors Human genes 0.000 claims 1
- 108010018951 Interleukin-8B Receptors Proteins 0.000 claims 1
- 229930184725 Lipoxin Natural products 0.000 claims 1
- 206010027417 Metabolic acidosis Diseases 0.000 claims 1
- 208000034486 Multi-organ failure Diseases 0.000 claims 1
- 208000010718 Multiple Organ Failure Diseases 0.000 claims 1
- 229910002651 NO3 Inorganic materials 0.000 claims 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 206010033647 Pancreatitis acute Diseases 0.000 claims 1
- BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 claims 1
- 102100038831 Peroxisome proliferator-activated receptor alpha Human genes 0.000 claims 1
- 102100038824 Peroxisome proliferator-activated receptor delta Human genes 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 206010069351 acute lung injury Diseases 0.000 claims 1
- 201000003229 acute pancreatitis Diseases 0.000 claims 1
- ASLUCFFROXVMFL-UHFFFAOYSA-N andrographolide Natural products CC1(CO)C(O)CCC2(C)C(CC=C3/C(O)OCC3=O)C(=C)CCC12 ASLUCFFROXVMFL-UHFFFAOYSA-N 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 208000029028 brain injury Diseases 0.000 claims 1
- 229960000530 carbenoxolone Drugs 0.000 claims 1
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 claims 1
- 239000000084 colloidal system Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 claims 1
- 229960001123 epoprostenol Drugs 0.000 claims 1
- 229940105423 erythropoietin Drugs 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 239000003572 glycogen synthase kinase 3 inhibitor Substances 0.000 claims 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 claims 1
- 229960004949 glycyrrhizic acid Drugs 0.000 claims 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 claims 1
- 235000019410 glycyrrhizin Nutrition 0.000 claims 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 150000002639 lipoxins Chemical class 0.000 claims 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 claims 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims 1
- 229960001476 pentoxifylline Drugs 0.000 claims 1
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 claims 1
- 108091008765 peroxisome proliferator-activated receptors β/δ Proteins 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229930015704 phenylpropanoid Natural products 0.000 claims 1
- 125000001474 phenylpropanoid group Chemical group 0.000 claims 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 claims 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 claims 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 229960004889 salicylic acid Drugs 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 210000000278 spinal cord Anatomy 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1109845.6A GB201109845D0 (en) | 2011-06-10 | 2011-06-10 | Artemisinin and its derivatives for use in the treatment of trauma haemorrhage and associated conditions |
| GB1109846.4 | 2011-06-10 | ||
| GBGB1109846.4A GB201109846D0 (en) | 2011-06-10 | 2011-06-10 | Artemisinin and its derivatives for use in medicine |
| GB1109847.2 | 2011-06-10 | ||
| GB1109845.6 | 2011-06-10 | ||
| GBGB1109847.2A GB201109847D0 (en) | 2011-06-10 | 2011-06-10 | Artemisinin and its derivatives for use in the treatment of myocardial infarction and coronary heart disease |
| PCT/EP2012/060929 WO2012168450A1 (en) | 2011-06-10 | 2012-06-08 | Artemisinin and its derivatives for use in the treatment of trauma haemorrhage and associated conditions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014517001A JP2014517001A (ja) | 2014-07-17 |
| JP2014517001A5 true JP2014517001A5 (enExample) | 2015-07-23 |
| JP6195561B2 JP6195561B2 (ja) | 2017-09-13 |
Family
ID=46245584
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014514097A Expired - Fee Related JP6195561B2 (ja) | 2011-06-10 | 2012-06-08 | 外傷出血および関連症状の治療における使用のための、アルテミシニンおよびその誘導体 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US9623005B2 (enExample) |
| EP (2) | EP3269371A1 (enExample) |
| JP (1) | JP6195561B2 (enExample) |
| ES (1) | ES2643182T3 (enExample) |
| WO (1) | WO2012168450A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3269371A1 (en) * | 2011-06-10 | 2018-01-17 | Queen Mary University of London | Artemisinin and its derivatives for use in the treatment of myocardial infarction or coronary heart disease |
| US9603831B2 (en) | 2012-12-12 | 2017-03-28 | Queen Mary & Westfield College, University Of London | Artemisinin and its derivatives for use in the treatment of kidney disease |
| CN104721874B (zh) * | 2014-12-23 | 2017-09-22 | 重庆联佰博超医疗器械有限公司 | 一种多糖止血粉及其制备方法、应用 |
| CN104523679A (zh) * | 2015-01-09 | 2015-04-22 | 中国人民解放军第三军医大学第一附属医院 | 青蒿琥酯在制备治疗、预防中枢神经损伤药物中的应用 |
| CN105147666A (zh) * | 2015-09-09 | 2015-12-16 | 云南大学 | 一种治疗和缓解神经变性疾病的化合物 |
| CN105963244A (zh) | 2016-01-15 | 2016-09-28 | 赵鸣 | 注射用青蒿琥酯制剂及其应用 |
| ES2651717B1 (es) * | 2016-07-26 | 2018-11-16 | Lara OLLER DUQUE | Solución acuosa cristaloide isotónica |
| KR20190067155A (ko) * | 2016-08-02 | 2019-06-14 | 유나이티 헬스 토론토 | 대뇌내 출혈 및 뇌 미세출혈의 발생률을 감소시키는 소분자 치료 화합물 |
| CN107793427A (zh) * | 2016-08-30 | 2018-03-13 | 天津太平洋制药有限公司 | 一种青蒿琥酯的制备方法 |
| EP3713566A4 (en) | 2017-11-21 | 2021-07-14 | Ming Zhao | TRIMERS AND TRETRAMERS OF ARTEMISININ AND THEIR USES |
| CN109364064A (zh) * | 2018-10-30 | 2019-02-22 | 澳门大学 | 青蒿素在防治脑卒中的应用 |
| CN109364061A (zh) * | 2018-10-30 | 2019-02-22 | 澳门大学 | 蒿甲醚在防治脑卒中的应用 |
| US11478200B2 (en) * | 2018-12-12 | 2022-10-25 | Covidien Lp | Blood pressure and autoregulation monitoring |
| CN111235098B (zh) * | 2020-01-17 | 2022-06-28 | 康妍葆(北京)干细胞科技有限公司 | 青蒿素在制备培养干细胞的产品中的应用、培养基及培养方法 |
| EP4015623A1 (en) * | 2020-12-17 | 2022-06-22 | Universite De Montpellier | Pre-treatment of msc with ppar beta/delta agonist for treatment of ischemia-reperfusion injury |
| US20240122987A1 (en) * | 2022-10-14 | 2024-04-18 | The Government Of The United States, As Represented By The Secretary Of The Army | Prolyl hydroxylase domain inhibitor treatment to improve survivability of hemorrhagic shock |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4922499A (en) | 1998-07-14 | 2000-02-07 | Hong Kong University Of Science & Technology, The | Trioxane derivatives |
| US7417156B2 (en) | 2002-09-27 | 2008-08-26 | Johns Hopkins University | Orally active, antimalarial, anticancer, artemisinin-derived trioxane dimers |
| EP1838301B1 (de) | 2004-12-28 | 2015-01-28 | Mestex AG | Verwendung von resiniferatoxin (rtx) für die herstellung eines mittels zur behandlung von schmerzen |
| CN1814601A (zh) | 2005-02-04 | 2006-08-09 | 中国科学院上海药物研究所 | 具有免疫抑制作用的青蒿素衍生物及药物组合物 |
| US8117654B2 (en) | 2006-06-30 | 2012-02-14 | The Invention Science Fund I, Llc | Implementation of malware countermeasures in a network device |
| WO2007125397A2 (en) | 2006-04-27 | 2007-11-08 | Vecta, Ltd. | Compositions and methods for inhibiting gastric acidity using endoperoxide bridge-containing compounds |
| JP5352454B2 (ja) | 2006-06-28 | 2013-11-27 | サノフイ | Ｃｘｃｒ２アンンタゴニスト |
| WO2008005276A2 (en) | 2006-06-30 | 2008-01-10 | Directcontact Llc | Growth factor delivery system containing antimicrobial agents |
| US20100137246A1 (en) | 2008-12-02 | 2010-06-03 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Anti-inflammatory compositions and methods |
| SG174483A1 (en) | 2009-03-24 | 2011-10-28 | Univ Singapore | Use of artemisinin derivatives for the treatment of asthma and chronic obstructive pulmonary disease (copd) |
| US9399032B2 (en) * | 2009-05-14 | 2016-07-26 | The General Hospital Corporation | Methods and compositions for treating degenerative and ischemic disorders |
| US8884032B2 (en) | 2009-05-19 | 2014-11-11 | The Johns Hopkins University | Trioxane monomers and dimers |
| US9737478B2 (en) | 2009-09-28 | 2017-08-22 | National Institutes of Health (NIH), U.S. Dept. of Health and Human Services (DHHS), The United States of America NIH Division of Extramural Inventions and Technology Resources (DEITR) | Treatment of malaria |
| GB201003734D0 (en) * | 2010-03-05 | 2010-04-21 | Univ Strathclyde | Delayed prolonged drug delivery |
| KR101277710B1 (ko) | 2010-09-07 | 2013-06-24 | 연세대학교 산학협력단 | 신규한 아테미시닌 또는 디옥소아테미시닌-당지질 복합유도체 및 그의 혈관신생억제 용도 |
| CN102552908B (zh) | 2010-10-12 | 2014-05-07 | 鼎泓国际投资（香港）有限公司 | 含青蒿素及青蒿素类衍生物和Bcl-2抑制剂的药物组合物及其应用 |
| EP3269371A1 (en) | 2011-06-10 | 2018-01-17 | Queen Mary University of London | Artemisinin and its derivatives for use in the treatment of myocardial infarction or coronary heart disease |
| US9603831B2 (en) * | 2012-12-12 | 2017-03-28 | Queen Mary & Westfield College, University Of London | Artemisinin and its derivatives for use in the treatment of kidney disease |
-
2012
- 2012-06-08 EP EP17186333.5A patent/EP3269371A1/en not_active Withdrawn
- 2012-06-08 WO PCT/EP2012/060929 patent/WO2012168450A1/en not_active Ceased
- 2012-06-08 JP JP2014514097A patent/JP6195561B2/ja not_active Expired - Fee Related
- 2012-06-08 ES ES12726622.9T patent/ES2643182T3/es active Active
- 2012-06-08 EP EP12726622.9A patent/EP2717879B1/en not_active Not-in-force
- 2012-06-08 US US14/125,032 patent/US9623005B2/en not_active Expired - Fee Related
-
2017
- 2017-03-07 US US15/452,065 patent/US9949948B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2988617T3 (es) | Norketotifeno para el tratamiento de la hipercitocinemia y las infecciones virales | |
| CY1120049T1 (el) | (2s)-ν-[(1s)-1-κυανο-2-φαινυλαιθυλ]-1,4-οξαζεπαν-2-καρβοξαμιδια ως αναστολεις της διπεπτιδυλικης πεπτιδασης i | |
| FI3256218T3 (fi) | Kdm1a-estäjät sairauksien hoidossa | |
| HRP20150770T1 (hr) | Terapijska kombinacija koja sadrži dolutegravir, abakavir i lamivudin | |
| HRP20151399T1 (hr) | Kinazni inhibitor koji regulira signalni put apoptoze | |
| HRP20171648T1 (hr) | Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze | |
| RU2016141570A (ru) | Комбинации ингибитора fgfr и ингибитора igf1r | |
| WO2021216530A1 (en) | Treatment of viral infections, of organ injury, and of related conditions using a hif prolyl hydroxylase inhibitor or a hif-alpha stabilizer | |
| BR112014015845A8 (pt) | derivados de azetidina, composições farmacêuticas e seu uso | |
| JP2014218522A5 (enExample) | ||
| US20170182000A1 (en) | Artemisinin And Its Derivatives For Use In The Treatment Of Trauma Haemorrhage And Associated Conditions | |
| JP2015510916A5 (enExample) | ||
| PT2576524T (pt) | Resumo | |
| ECSP19027780A (es) | Derivados de 5-[2-(piridin-2-ilamino)-1,3-tiazol-5-il]-2,3-dihidro-1h-isoindol-1-ona y su uso como inhibidores dobles de fosfatidilinositol 3-cinasa delta y gamma | |
| Sun et al. | Aminopeptidase N inhibitor 4cc synergizes antitumor effects of 5-fluorouracil on human liver cancer cells through ROS-dependent CD13 inhibition | |
| JP2018531273A5 (enExample) | ||
| RU2014112324A (ru) | Применение органического соединения для лечения синдрома нунан | |
| JP2016515550A5 (enExample) | ||
| RS59303B1 (sr) | Spojnica | |
| BR112016011811A2 (pt) | Uso de um inibidor de fosfatidilinositol 3-cinase seletivo de alfa-isoforma, regime terapêutico e pacote | |
| RU2016115374A (ru) | Фармацевтические композиции, содержащие антибактериальные агенты | |
| RU2011134414A (ru) | Комбинация фульвовой кислоты для лечения различных состояний и болезней | |
| RU2015111491A (ru) | Комбинация макроциклического ингибитора протеазы hcv, ненуклеозидного ингибитора hcv и ритонавира | |
| JP2009533428A (ja) | 筋肉内抗ウイルス処置 | |
| JP2019511996A5 (enExample) |